* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Advanced Accelerator Applications's EV-to-EBIT
For the Biotechnology subindustry, Advanced Accelerator Applications's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Accelerator Applications's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advanced Accelerator Applications's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Advanced Accelerator Applications's EV-to-EBIT falls into.
Advanced Accelerator Applications's current Enterprise Value is $3,605.6 Mil.
Advanced Accelerator Applications's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Advanced Accelerator Applications's Enterprise Value for the quarter that ended in Sep. 2017 was $2,649.9 Mil.
Advanced Accelerator Applications's EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Accelerator Applications EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Advanced Accelerator Applications's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Advanced Accelerator Applications (Advanced Accelerator Applications) Business Description
Advanced Accelerator Applications SA is a French-based radiopharmaceutical company. It develops, produces, and commercializes molecular nuclear medicine diagnostic and therapeutic products. The molecular nuclear medicine is a medical specialty that uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases including cancer. The company includes a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its PET and SPECT are imaging techniques in molecular nuclear diagnostics with applications in clinical oncology, cardiology and neurology. Its other diagnostic product is Gluscan, its branded fluorodeoxyglucose PET imaging agent.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AAAP has been successfully added to your 